Home » Stocks » Heska Corporation

Heska Corporation (HSKA)

Stock Price: $106.54 USD 0.44 (0.41%)
Updated Aug 14, 2020 9:41 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.01B
Revenue (ttm) 141.37M
Net Income (ttm) -13.68M
Shares Out 9.44M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE 243.90
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $106.54
Previous Close $106.10
Change ($) 0.44
Change (%) 0.41%
Day's Open 106.10
Day's Range 106.10 - 106.54
Day's Volume 1,767
52-Week Range 50.00 - 110.90

More Stats

Market Cap 1.01B
Enterprise Value 978.82M
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 9.44M
Float 8.84M
EPS (basic) -1.7
EPS (diluted) -1.76
FCF / Share -0.59
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 576,963
Short Ratio 8.22
Short % of Float 6.39%
Beta 1.67
PE Ratio n/a
Forward PE 243.90
P/FCF Ratio n/a
PS Ratio 7.12
PB Ratio 3.57
Revenue 141.37M
Operating Income -8.10M
Net Income -13.68M
Free Cash Flow -5.17M
Net Cash 27.27M
Net Cash / Share 2.89
Gross Margin 38.52%
Operating Margin -5.73%
Profit Margin -9.70%
FCF Margin -3.66%
ROA -0.32%
ROE -7.19%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 2
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$96.17*
(-9.73% downside)
Low
62.0
Current: $106.54
High
116.5
Target: 96.17
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12312712913010589.8478.3472.8170.0765.45
Revenue Growth-3.75%-1.47%-0.57%24.37%16.43%14.68%7.6%3.91%7.05%-
Gross Profit54.4556.6458.2653.8944.2135.7230.6331.1029.1924.79
Operating Income0.333.7918.2216.538.562.91-1.432.163.250.36
Net Income-1.475.859.9510.515.242.60-1.201.202.150.02
Shares Outstanding7.457.227.036.786.515.955.765.335.245.22
Earnings Per Share-0.200.741.301.430.740.41-0.210.220.40-
EPS Growth--43.08%-9.09%93.24%80.49%---45%--
Operating Cash Flow3.3013.2910.415.862.135.55-1.41-0.374.891.94
Capital Expenditures-1.04-4.08-3.41-3.42-3.77-2.333.09-1.51-1.08-0.62
Free Cash Flow2.259.207.002.44-1.653.221.68-1.883.801.32
Cash & Equivalents92.8916.389.6610.796.895.866.025.786.335.49
Total Debt52.636.006.000.750.370.425.302.55-3.08
Net Cash / Debt40.2610.383.6610.046.525.440.723.236.332.41
Assets24415613513111096.8493.5566.8361.8963.05
Liabilities89.8934.0435.0043.8730.4428.0329.3717.9613.4617.25
Book Value15412210086.9847.7837.4533.4648.8648.4445.80
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Heska Corporation
Country United States
Employees 386
CEO Kevin S. Wilson

Stock Information

Ticker Symbol HSKA
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: HSKA
IPO Date June 30, 1997

Description

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.